A probiotic way to say no to Diabetes: Probiotic MIYAIRI 588-based therapy for diabetes (TIDM): Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 17/December/2018, 11.58 pm